Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

by lowes1 on October 7, 2013

Condition:   Advanced Stage Non Small Cell Lung Cancer
Interventions:   Drug: Erlotinib 100mg qd;   Drug: Gefitinib 250mg qd
Sponsors:   Sun Yat-sen University;   Sun Yat-sen University
Recruiting – verified September 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: